An interventional study of 75g glucose beverage (Glucola, Trutol, or similar brand) and DXA, whole body in Diabetes Mellitus, Type 2 and Genetics, sponsored by University of Pennsylvania. Recruiting at 2 sites in United States. Open to participants aged 10 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-21.
Sponsored by University of Pennsylvania · Not applicable, Interventional, and Other
Among 17 studies in Diabetes Mellitus, Type 2 by University of Pennsylvania — 3 open to participants now, 5 under way, none of them phase 3. Diabetes Mellitus, Type 2 · University of Pennsylvania.
Among the 17 studies in Diabetes Mellitus, Type 2 by University of Pennsylvania, this one is the 6th largest by planned enrollment of the 14 interventional ones that give a count, is one of 2 that started in 2019, is one of 10 with no phase, and was the 13th registered.
10,371 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,406 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →3 of the 17 studies in Diabetes Mellitus, Type 2 by University of Pennsylvania are open now, in 1 country. Recruiting first, the newest first:
University of Pennsylvania · Sites in United States
Ages 18+ · Healthy volunteers
University of Pennsylvania · Sites in United States
Ages 50+
By country, each count listing its studies:
Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 373 (42%) set no upper age limit and 384 (43%) stop at 75 or younger; 52 take children under 18; 203 take healthy volunteers.
This study: 10 Years to 70 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 2 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is above the median of 80 across 8,350 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 66 across the 14 interventional studies, 102 across the 3 observational. Of the 11 that completed or were terminated, 2 (18%) have results posted.
This tab as a report to print or save as PDF → With an account.
University of Pennsylvania is the lead sponsor of 1,668 studies on the registry; 234 are open to participants now.
Of its 158 completed or terminated interventional studies of FDA-regulated products, 110 (70%) have results posted.
3 of the studies in Diabetes Mellitus, Type 2 by University of Pennsylvania that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07167004University of PennsylvaniaThe GRoceries Aimed at Increasing Nutrition Study | 2027-02-16 |
| NCT07444203University of PennsylvaniaTransformative Research in Diabetic Nephropathy 2.0 | 2027-05-30 |
| NCT04024631University of PennsylvaniaPhenotyping Genetic Risk for Type 2 Diabetes | 2027-06-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 17 studies in Diabetes Mellitus, Type 2 by University of Pennsylvania, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study tests the hypothesis that non-diabetic individuals with a high genetic risk score for type 2 diabetes have impaired glucose tolerance and insulin resistance compared to those with a low genetic risk score for type 2 diabetes.
The study team will recruit individuals based on genetic risk score for type 2 diabetes from the biobank populations who have agreed to be recontacted for future research. Each participant will undergo a frequently sampled four-hour oral glucose tolerance test and whole body DXA scan (dual-energy X-ray absorptiometry) in addition to baseline laboratory and history assessment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All participants will undergo a four-hour frequently sampled oral glucose tolerance test in which they will ingest a 75g glucose beverage (intervention) within five minutes and have samples collected at baseline and for four hours after. They will also undergo a whole body DXA (intervention) during the study day.
Other: 75g glucose beverage (Glucola, Trutol, or similar brand) · Other: DXA, whole body
Subjects will present fasting to the study day and ingest the glucose beverage during the oral glucose tolerance test.
Subjects will undergo a whole body DXA scan for assessment of adiposity index and body fat distribution.
Glucose response to an oral glucose load
Glucose area under the curve after the 75g glucose beverage
Time frame: samples will be collected over four hours and these results will be used to calculate area under the curve
Visceral adiposity index
DXA whole body scan visceral adiposity index
Time frame: DXA scan will be obtained on the same day as the oral glucose test and will be completed in less than 30 minutes
HOMA-IR
Insulin resistance estimate
Time frame: calculated from baseline fasting insulin and glucose levels
Disposition index
product of insulin sensitivity and amount of insulin released; calculated using mixed modeling techniques
Time frame: samples will be collected over four hours after the 75g glucose beverage and these results will be used for mixed modeling
Plan to share: No
No publications or documents are linked to this record.
Started Jun 2019 (actual). Primary completion is estimated for Jun 2027, 96 months after the start.
Of 2,066 non-industry interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's planned 96 months is above that.
Counting every sponsor, half of 2,243 studies reached it within 21 months; a quarter within 10 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.